Find comprehensive information on Aripiprazole (Abilify, Aristada, Abilify Maintena) for accurate clinical documentation and medical coding. Learn about Aripiprazole diagnosis, administration, and potential adverse effects. This resource supports healthcare professionals in proper coding and documentation practices related to Aripiprazole treatment, ensuring compliance and optimized patient care. Explore details on Abilify, Aristada, and Abilify Maintena for precise clinical records.
Also known as
Other psychoactive substance abuse
Covers abuse of other psychoactive substances, including aripiprazole.
Mental and behavioural disorders due to psychoactive substance use
Encompasses a range of mental disorders related to substance use, potentially including aripiprazole misuse.
Drugs, medicaments and biological substances causing adverse effects in therapeutic use
Includes adverse effects from drugs like aripiprazole when used therapeutically.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Aripiprazole use causing adverse effects?
When to use each related code
| Description |
|---|
| Atypical antipsychotic for schizophrenia, bipolar disorder, and depression. |
| Atypical antipsychotic similar to aripiprazole, for schizophrenia and bipolar disorder. |
| Antipsychotic often used for schizophrenia and bipolar disorder when other treatments fail. |
Coding for unapproved indications like anxiety or insomnia without proper documentation creates compliance and billing risks.
Incorrect coding for oral (Abilify) vs. injectable (Aristada, Abilify Maintena) can lead to claim denials and revenue loss.
Failure to accurately code co-existing conditions like schizophrenia or bipolar disorder with aripiprazole impacts reimbursement and quality metrics.
Q: What are the most effective strategies for managing aripiprazole weight gain in patients with schizophrenia, considering both pharmacological and non-pharmacological interventions?
A: Aripiprazole, while effective for schizophrenia, can lead to weight gain, a significant concern for long-term management. Strategies for mitigating this include careful monitoring of weight and metabolic parameters, dietary counseling emphasizing a balanced, calorie-controlled diet, and encouraging regular physical activity. Pharmacologically, switching to a lower dose or a different antipsychotic with a lower propensity for weight gain, such as ziprasidone or lurasidone, can be considered. Metformin has shown some promise as an adjunctive treatment in mitigating aripiprazole-induced weight gain. However, any changes should be made in consultation with the patient and after careful consideration of their overall clinical picture. Explore how a multidisciplinary approach involving psychiatrists, dieticians, and exercise specialists can optimize patient outcomes. Consider implementing a standardized protocol for weight monitoring and intervention in your practice.
Q: How do I differentiate akathisia caused by aripiprazole from the restlessness sometimes seen in schizophrenia itself, and what are the best management approaches?
A: Differentiating aripiprazole-induced akathisia from the intrinsic restlessness of schizophrenia can be challenging. Akathisia typically presents as subjective inner restlessness and an inability to sit still, accompanied by objective signs like pacing, rocking, or foot-tapping. In contrast, the restlessness in schizophrenia is often more disorganized and less clearly defined. Careful history taking, including the timing of symptom onset in relation to aripiprazole initiation or dose adjustment, is crucial. Consider using standardized rating scales like the Barnes Akathisia Rating Scale (BARS) to assess the severity of akathisia. Management strategies include reducing the aripiprazole dose or switching to a different antipsychotic. Beta-blockers, such as propranolol, or anticholinergic medications, like benztropine, can be used for symptomatic relief. Learn more about the specific benefits and risks associated with each intervention to tailor your approach to individual patient needs.
Patient presents for follow-up management of schizophrenia, diagnosed via DSM-5 criteria. The patient reports continued improvement in positive symptoms such as auditory hallucinations and delusional thinking since initiating aripiprazole therapy. Current medication regimen includes aripiprazole (Abilify Maintena) administered intramuscularly monthly. Patient denies any current suicidal or homicidal ideation. Mental status examination reveals clear speech, organized thought processes, and appropriate affect. Patient reports mild akathisia, managed with propranolol. No other extrapyramidal symptoms or adverse effects noted. Assessment: Schizophrenia, stable on current aripiprazole treatment. Plan: Continue aripiprazole Maintena at current dosage. Monitor for efficacy and tolerability, including akathisia, and adjust propranolol as needed. Patient education provided regarding medication adherence, potential side effects, and importance of follow-up appointments. ICD-10 code F20.9 (Schizophrenia, unspecified) and CPT code 90837 (Individual psychotherapy) applied for this session. Next appointment scheduled in four weeks to coincide with next injection. Discussed medication management, including the benefits of long-acting injectable aripiprazole (Aristada, Abilify Maintena) for improved adherence and relapse prevention. Emphasis placed on the importance of shared decision-making in antipsychotic selection and dosage adjustment.